Loading...
Market
When will TERN-601 Phase 2 trial results be announced?
2
Resolution / Starting Odds
Q1 2025 • 25%
Q2 2025 • 25%
After Q2 2025 • 25%
No announcement by mid-2025 • 25%
Terns Pharmaceuticals official announcements, clinical trial registries
Story
Terns Pharmaceuticals Stock Soars 10% After Positive Phase 1 Trial Results Showing 5.5% Weight Loss
Sep 9, 2024, 11:09 AM
Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for its once-daily oral GLP-1R agonist, TERN-601, aimed at treating obesity. The trial demonstrated a statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo-adjusted weight loss. The study also reported the absence of treatment-related dose interruptions, reductions, or discontinuations, with mostly mild adverse events, despite aggressive titration to high doses. Following this announcement, Terns Pharmaceuticals' stock soared by 10%.
View original story
Similar markets
Yes • 50%
No • 50%
Mean weight loss < 5% • 25%
Mean weight loss 5% to 7% • 25%
Mean weight loss 7% to 9% • 25%
Mean weight loss > 9% • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
No Results • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%